Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Fluconazole Versus Fluconazole And MGCD290 for the Treatment of Moderate to Severe Vulvovaginal Candidiasis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Feb 2014
Price :
$35
*
At a glance
- Drugs MGCD 290 (Primary) ; Fluconazole
- Indications Vulvovaginal candidiasis
- Focus Therapeutic Use
- 18 Mar 2013 Status changed from active, no longer recruiting to completed.
- 18 Mar 2013 Results published in the Media Release.
- 18 Mar 2013 Primary endpoint 'Therapeutic-cure-rate' has not been met, according to a Methylgene media release.